Characterization of SU(1,1) coherent states in terms of affine group wavelets

The Perelomov coherent states of SU(1,1) are labeled by elements of the quotient of SU(1,1) by the compact subgroup. Taking advantage of the fact that this quotient is isomorphic to the affine group of the real line, we are able to parameterize the coherent states by elements of that group or equivalently by points in the half-plane. Such a formulation permits to find new properties of the SU(1,1) coherent states and to relate them to affine wavelets.Comment: 11 pages, latex, to be published in J. Phys. A : Math. Ge

Tecnologie Digitali e DSA

Il termine “strumento compensativo”, concetto essenziale nel percorso educativo degli studenti con DSA, è spesso fonte di dubbio per genitori, insegnanti e ragazzi: quali sono gli strumenti compensativi digitali presenti sul mercato? Uno strumento vale l’altro? Come si fa a scegliere quello giusto? Per contribuire a rispondere a queste domande è stata redatta una “rassegna ragionata” di 233 tecnologie digitali, raccogliendo informazioni sugli strumenti utilizzati da docenti, esperti, genitori e studenti con DSA. La rassegna offre un aiuto per orientarsi tra le varie opportunità e attuare una scelta consapevole delle tecnologie compensative a supporto dell’apprendimento e dello studio autonomo

Carrier-phase DNS study of particle size distribution effects on iron particle ignition in a turbulent mixing layer

The ignition and combustion of iron particles in a turbulent mixing layer is studied by means of three-dimensional carrier-phase direct numerical simulations (CP-DNS). A particular focus is set on particle size distribution (PSD) effects on the ignition behaviour by comparing CP-DNS results from using a realistic experimental PSD to DNS data based on a monodisperse (MD) particle cloud with the same equivalence ratio. The CP-DNS solves the Eulerian transport equations of the reacting gas phase and resolves all turbulent scales, while the particle boundary layers are modelled in the Lagrangian point-particle framework. A previously validated sub-model for the oxidation of iron to Wüstite (FeO) that accounts for both diffusion- and kinetically-limited combustion is employed. The mixing layer is initialised with an upper stream of air carrying cold iron particles and an opposed lower stream of hot air. Simulation results show distinct differences in the ignition behaviour between the MD and PSD cases. The ignition of the PSD case is delayed compared to the MD case and does not show any significant particle clustering prior to ignition. Further investigations indicate that the particle size has a crucial effect on the mixing process and ignition time. Small particles start their oxidation process early and already consume some of the available oxygen, while not crucially affecting the gas temperature due to their limited iron mass contribution. Conversely, a slower entrainment into the lower stream combined with higher thermal inertia and the prior oxygen depletion by the small particles leads to a delayed oxidation of the larger particles. As a net result, the PSD case shows a wide spread of individual particle ignition delay times and overall delayed bulk ignition compared to the MD case, where the majority of the particles ignites over a shorter period of time

Lawson criterion for ignition exceeded in an inertial fusion experiment

For more than half a century, researchers around the world have been engaged in attempts to achieve fusion ignition as a proof of principle of various fusion concepts. Following the Lawson criterion, an ignited plasma is one where the fusion heating power is high enough to overcome all the physical processes that cool the fusion plasma, creating a positive thermodynamic feedback loop with rapidly increasing temperature. In inertially confined fusion, ignition is a state where the fusion plasma can begin "burn propagation" into surrounding cold fuel, enabling the possibility of high energy gain. While "scientific breakeven" (i.e., unity target gain) has not yet been achieved (here target gain is 0.72, 1.37 MJ of fusion for 1.92 MJ of laser energy), this Letter reports the first controlled fusion experiment, using laser indirect drive, on the National Ignition Facility to produce capsule gain (here 5.8) and reach ignition by nine different formulations of the Lawson criterion

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049